Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × lanreotide × Clear all

Phase

Status

Completed 4 Recruiting 3 Terminated 2 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Serotonin Syndrome 1 Carcinoid Heart Disease 1

Interventions

Cisplatin 17 Carboplatin 11 Radiotherapy 10 Paclitaxel 9 Fluorouracil 8 Rituximab 7 Gemcitabine 7 Capecitabine 5 Vinorelbine 4 Nivolumab 4 Drug Therapy 4 Docetaxel 4 Bevacizumab 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 Trastuzumab 3 Standard of Care 3 Pemetrexed 3 Oxaliplatin 3 Etoposide 3 Dexamethasone 3 Cyclophosphamide 3 Cetuximab 3 Bendamustine Hydrochloride 3 parsaclisib 2 linrodostat 2 lenvatinib 2 human papillomavirus vaccine, L1 type 16, 18 2 fludarabine phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡